PALO ALTO, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TOKYO:4502) today announced that Affymax has dosed the first patient in the Phase 3 clinical program of its lead investigational therapy, Hematide™, for the treatment of anemia in chronic renal failure patients.
